Human monoclonal antibody HCV1 effectively prevents and treats HCV infection in chimpanzees
about
Identification of rodent homologs of hepatitis C virus and pegivirusesStatus of hepatitis C virus vaccination: Recent updateHepatitis C virus: why do we need a vaccine to prevent a curable persistent infection?Genetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine DesignImpact of lipids and lipoproteins on hepatitis C virus infection and virus neutralizationBivalent vaccine platform based on Japanese encephalitis virus (JEV) elicits neutralizing antibodies against JEV and hepatitis C virusMouse Systems to Model Hepatitis C Virus Treatment and Associated ResistanceStructural evidence for a bifurcated mode of action in the antibody-mediated neutralization of hepatitis C virusStructural Basis of HCV Neutralization by Human Monoclonal Antibodies Resistant to Viral Neutralization EscapeAn alpaca nanobody inhibits hepatitis C virus entry and cell-to-cell transmissionUnexpected structural features of the hepatitis C virus envelope protein 2 ectodomain.Capitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine designA Hepatitis C Virus Envelope Polymorphism Confers Resistance to Neutralization by Polyclonal Sera and Broadly Neutralizing Monoclonal AntibodiesOptimization of peptide arrays for studying antibodies to hepatitis C virus continuous epitopes.The core domain of hepatitis C virus glycoprotein E2 generates potent cross-neutralizing antibodies in guinea pigsBroadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearanceIn Silico Identification and Conservation Analysis of B-cell and T-Cell Epitopes of Hepatitis C Virus 3a Genotype Enveloped Glycoprotein 2 From Pakistan: A Step Towards Heterologous Vaccine DesignNon-random escape pathways from a broadly neutralizing human monoclonal antibody map to a highly conserved region on the hepatitis C virus E2 glycoprotein encompassing amino acids 412-423Fine mapping of murine antibody responses to immunization with a novel soluble form of hepatitis C virus envelope glycoprotein complex.Exosomes from hepatitis C infected patients transmit HCV infection and contain replication competent viral RNA in complex with Ago2-miR122-HSP90.The Humoral Immune Response to HCV: Understanding is Key to Vaccine Development.Recombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization.Will there be a vaccine to prevent HCV infection?Determination of the human antibody response to the neutralization epitopes encompassing amino acids 313-327 and 432-443 of hepatitis C virus E1E2 glycoproteinsBroadly neutralizing antibodies abrogate established hepatitis C virus infectionHigh-throughput sequencing analysis of post-liver transplantation HCV E2 glycoprotein evolution in the presence and absence of neutralizing monoclonal antibody.Breadth of neutralization and synergy of clinically relevant human monoclonal antibodies against HCV genotypes 1a, 1b, 2a, 2b, 2c, and 3a.Immunoglobulin with High-Titer In Vitro Cross-Neutralizing Hepatitis C Virus Antibodies Passively Protects Chimpanzees from Homologous, but Not Heterologous, ChallengeNanopore-Based Target Sequence Detection.Applying antibody-sensitive hypervariable region 1-deleted hepatitis C virus to the study of escape pathways of neutralizing human monoclonal antibody AR5A.Monoclonal Antibodies Directed toward the Hepatitis C Virus Glycoprotein E2 Detect Antigenic Differences Modulated by the N-Terminal Hypervariable Region 1 (HVR1), HVR2, and Intergenotypic Variable RegionPrevention of hepatitis C virus infection using a broad cross-neutralizing monoclonal antibody (AR4A) and epigallocatechin gallateHuman monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation: a randomized controlled study.Effect of scavenger receptor class B type I antagonist ITX5061 in patients with hepatitis C virus infection undergoing liver transplantation.Humanized mice for the study of infectious diseases.Altered Glycosylation Patterns Increase Immunogenicity of a Subunit Hepatitis C Virus Vaccine, Inducing Neutralizing Antibodies Which Confer Protection in Mice.Global mapping of antibody recognition of the hepatitis C virus E2 glycoprotein: Implications for vaccine design.Native Folding of a Recombinant gpE1/gpE2 Heterodimer Vaccine Antigen from a Precursor Protein Fused with Fc IgG.Virus-like particle-based vaccines against hepatitis C virus infection.Virus-neutralizing antibodies to hepatitis C virus.
P2860
Q24634479-F255AA18-ECE6-4A67-87B7-CE540D2A9960Q26774612-0E0E83A9-8253-4E6C-B2D5-5EC87807ADCAQ26799141-F9913794-4B1A-4F2E-9869-6DBED8B46CFFQ26801759-704CD9B6-94D8-4ED9-92D5-8741B3F51370Q26864485-D40F2EC4-4BD1-4B3E-845A-720E3DF1E115Q27469019-842DF445-0A1B-4C55-BFAD-A49FF1371752Q27469038-994E712B-166C-441D-9E74-8D6B3D512D3CQ27677400-623B4AFE-FE31-42CF-9C95-A426072DC125Q27678252-715F47CF-C914-4AC1-A009-8E9AB2852B01Q27684354-EA0868DE-2D1B-4FA9-B75F-A8C2EA1AA931Q30364309-4CA8BAA6-C752-4C28-8723-99D432537F8AQ30374314-644C4ECC-2954-4123-9D6D-1B31F855522AQ30383939-51C5E83F-9BCD-4EE8-AC35-DBFFB2E1D249Q33563569-53D9AFCE-9004-488A-9EE8-C5129E37341FQ33612608-1A874930-1D5A-42E9-ACD5-8DFC7F58310CQ33631104-229CD096-E9E6-4FB4-B48D-34418370B34EQ33808123-5DF6CEE7-D98E-4358-A529-8DD03A7071CEQ34047477-A36E1416-480F-41F5-9833-D31FD40CF0D7Q34262165-1979E6C8-E590-4A92-8FA7-6042655A4FF7Q34282491-CD236C50-A9F6-432B-973E-BF2012E0576DQ34481429-C6EB3507-BBB5-4D06-AC8B-B59A7E8AC1FEQ34594986-849D2C0D-7F95-4530-A388-27874F66B8F5Q34781537-5376C262-8461-47B8-A1C3-DDB1734199F5Q34796179-A67427C5-C3EF-4F61-8672-3B5594E3672AQ35032263-C48C2F8E-4F57-441E-8ED2-8AA8F79C39C7Q35193285-3973B98E-0157-49AA-BE92-78C7DBCA8D55Q35557994-F82E8906-E9A0-4D16-AF6B-2424752D03C2Q35913863-828857D0-F312-43DA-8C17-61DE45509BAAQ36009823-D948068B-505D-407F-BC96-2AF672F60B46Q36288404-A31CFCB4-A0DC-42DC-ACA7-642DE2360F67Q36334312-242CC633-2724-4D2E-9056-8A9EF9C3FA9BQ36624431-A90EDBA6-3769-445A-A871-506A000567CAQ36745425-6AD565F2-DBEB-427D-9D63-4BA8104D53B7Q36990362-9EBBDFBA-9DFD-4372-A38A-879DF0417578Q37179146-42520E61-A6CA-4C50-964D-7F75D0F8D282Q37415463-CE41D119-AD35-44D7-ADE6-929604AC6302Q37417999-152F013F-9931-4AF4-951B-061F3D49DDB4Q37512845-811047F1-52E0-4BEB-89A7-982315101706Q38081966-890E741E-A512-4624-B500-BFDCF0068F90Q38104471-D40292A3-C5F8-45D1-BB7B-D159F8F1B60F
P2860
Human monoclonal antibody HCV1 effectively prevents and treats HCV infection in chimpanzees
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Human monoclonal antibody HCV1 ...... s HCV infection in chimpanzees
@ast
Human monoclonal antibody HCV1 ...... s HCV infection in chimpanzees
@en
Human monoclonal antibody HCV1 ...... s HCV infection in chimpanzees
@nl
type
label
Human monoclonal antibody HCV1 ...... s HCV infection in chimpanzees
@ast
Human monoclonal antibody HCV1 ...... s HCV infection in chimpanzees
@en
Human monoclonal antibody HCV1 ...... s HCV infection in chimpanzees
@nl
prefLabel
Human monoclonal antibody HCV1 ...... s HCV infection in chimpanzees
@ast
Human monoclonal antibody HCV1 ...... s HCV infection in chimpanzees
@en
Human monoclonal antibody HCV1 ...... s HCV infection in chimpanzees
@nl
P2093
P2860
P3181
P1433
P1476
Human monoclonal antibody HCV1 ...... s HCV infection in chimpanzees
@en
P2093
Barbra M Blair
Brett A Leav
David B Olsen
Deborah C Molrine
Donna M Ambrosino
Elisabeth N Boucher
Gregory J Babcock
Gyongyi Szabo
Michael Knauber
Peter S Cheslock
P2860
P304
P3181
P356
10.1371/JOURNAL.PPAT.1002895
P407
P577
2012-01-01T00:00:00Z